HCV-HIV co-infected patients: No longer a 'special' population?

Liver International

Volumn 36, Issue , 2016, Pages 43-46

  Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Direct acting antivirals; Hepatitis C virus; Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; INTERFERON; UNCLASSIFIED DRUG;

CHRONIC HEPATITIS C; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; OUTCOME ASSESSMENT; PATIENT SAFETY; POPULATION; PRACTICE GUIDELINE; REINFECTION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; COINFECTION; DRUG INTERACTION; HIV INFECTIONS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; TREATMENT OUTCOME;

EID: 84952837137     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13021     Document Type: Review

References (20)

1. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199-206.
2. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
3. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients - a randomized controlled trial. JAMA J Am Med Assoc 2004; 292: 2839-48.
4. van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther. 2013; 18: 105-13.
5. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013; 56: 718-26.
6. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20: 2361-9.
7. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-954.
8. European Association for Study of Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
9. Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 705-13.
10. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313: 1223-31.
11. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 714-25.
12. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2: e319-27.
13. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-9.
14. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
15. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384: 241-8.
16. Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men: a systematic review and meta-analysis. AIDS 2015; 29: 2335-45.
17. Hill AM, Simmons B, Saleem J, Cooke G. Five-year risk of late relapse or reinfection with hepatitis C after sustained virological response: meta-analysis of 49 studies in 8534 patients. CROI 2015; February 23-26, 2015. Seattle, Washington. Abstract number 654.
18. Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.
19. Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008; 47: 1468-75.
20. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.